NitroMed's BiDil Pricing: Test for a Whole Class of New Companies

After putting two generics together and then getting the product approved for a new indication, NitroMed priced its new drug above expectations. But will the old-style pricing strategy hold up in a managed care world?

Ellen Licking

These have been heady days for NitroMed Inc. On June 23, the Food and Drug Administration approved the company's...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo